Table 1.
Characteristics of 13 AML patients with EZH2 mutations.
Table 2.
Comparison of clinical and laboratory features between AML patients with and without EZH2 mutation.
Figure 1.
Kaplan-Meier survival curves according to EZH2 mutation status.
(A) EFS in de novo AML patients according to EZH2 mutations. The green line represents patients with mutated EZH2 (n = 12); and magenta line, patients with unmutated EZH2 (n = 277; P = 0.2283); (B) OS in de novo AML patients according to EZH2 mutations. The green line represents patients with mutated EZH2 (n = 12); and the magenta line represents patients with unmutated EZH2 (n = 277; P = 0.5001).